| Report Name | Report Type | Specialty | Publish Date | |
|---|---|---|---|---|
| Diabetes: GLP-1 Analogues, DPP-IV Inhibitors & Insulins Trends in Use | Survey | Endocrinology | Sep 10, 2007 | PAID REPORT |
| To provide an overview of current type II diabetes mellitus (T2DM) treatment practices and the near-term market outlook for a set of companies and key therapeutic products in development. Additionally: Focus on experience with and outlook for three key drugs and classes:... | ||||
| Insulin Analogues: Market Assessment | Discussion | Endocrinology | Aug 14, 2007 | PAID REPORT |
| Panel Intelligence engaged a panel of ten endocrinologists and primary care physicians to: Evaluate the growth in the diabetes market, specifically focused on insulin analogues. Areas investigated: o Choice of product by patient type and other... | ||||
| Insulin Pumps: Trends in Use | Discussion | Endocrinology | Aug 14, 2007 | PAID REPORT |
| To conduct a panel among diabetologists to discuss the use of continuous subcutaneous insulin injection therapy in patients with type 1 and type 2 diabetes. The primary goals are to understand current treatment practices and market dynamics involving insulin pumps, and to determine physician and... | ||||
| Diabetic Foot Infection (Mild): Trends in Treatment | Discussion | Endocrinology | Jun 14, 2007 | PAID REPORT |
| Panel Intelligence engaged a panel of podiatrists in a discussion designed to understand the perception and potential use of Microcyn� technology for the treatment of mild diabetic foot infections. Uncover current treatment patterns for mild diabetic foot infections ... | ||||
| American Diabetes Association 2007 Leadership Summit | Discussion | Endocrinology | Jun 14, 2007 | PAID REPORT |
| Discuss the GLP-1 analogues: the current use of exenatide, the status of exenatide LAR and an update on liraglutide. Review the use of DPP-IV inhibitors Current practice with Januvia Status of Galvus Market of DPP-IV inhibitors ... | ||||
| TRT for Hypogonadism | Discussion | Endocrinology | Mar 28, 2007 | FREE |
| n Compare and contrast current treatment options for testosterone replacement therapy (TRT) n Elicit expert feedback on testosterone undecanoate (Indevus�s Nebido) n Clarify potential utilization of testosterone undecanoate ... | ||||
| Discussion Diabetes-Byetta Usage and Diabetes Market Trends_MAR2007 | Discussion | Endocrinology | Mar 7, 2007 | FREE |
| Determine current treatment patterns, recent market dynamics, and future trends with the mix of leading Type 2 therapies, including Byetta (exenatide), Januvia (sitagliptin) and Other standards of care (metformin, TZD�s, sulfonylureas, insulin) ... | ||||
| Impact of Januvia and Galvus on Type 2 Diabetes Market | Discussion | Endocrinology | Dec 17, 2006 | FREE |
| Elicit prescribers� perceptions of Januvia Determine the facilitators and barriers to Januvia use Understand the typical Januvia patient profile Establish the impact of Januvia�s approval on the use of other agents (Actos/Avandia, Insulin, Byetta) and expected trends Ascertain... | ||||
| Type 2 Diabetes Therapies Assessment | Discussion | Endocrinology | Dec 14, 2006 | FREE |
| Determine current usage/allocation of the mix of leading Type 2 therapies Understand utilization Understand physician prescribing experience with exenatide Assess impact of sitagliptin on treatment algorithms Gather impressions of inhaled insulin Products Highlighted: ... | ||||
| Evaluation of Byetta | Survey | Endocrinology | Jul 30, 2006 | FREE |
| To assess current physician opinion and prescribing practices of Byetta for patients with type II diabetes To evaluate current patient perceptions of Byetta To estimate future use of Byetta over the next twelve months To gauge physician awareness and familiarity with emerging... | ||||
| ADA Diabetes Forum | Discussion | Endocrinology | Jun 20, 2006 | FREE |
| To examine data emerging from the American Diabetes Association�s (ADA) 66th Annual Scientific Sessions To investigate strengths and weaknesses associated with diabetes treatments currently in development To prioritize treatment objectives for diabetic patients Products... | ||||
| © Panel Intelligence, LLC. 1999-2008. All rights reserved. A wholly owned subsidiary of MCF Corporation (NASDAQ: MERR) Privacy Policy |